Obinutuzumab:Targeting The CD’s Of CLL.

CD20 is a cell surface protein commonly found in B-cell chronic lymphocytic leukemia (CLL). In physically fit patients with previously untreated CLL, chemotherapy and the monoclonal CD20 antibody rituximab can significantly increase overall survival (OS). However, in patients in poor health or in patients that have existing CLL, this approach is not an option.

Obinutuzumab, is a third generation type II anti-CD20 antibody that selectivity binds to CD20 antigen on malignant human B cells, resulting in enhanced antibody dependent cellular cytotoxicity (ADCC) and programmed cell death (apoptosis).

In a recent clinical trial on 781 elderly patients (median age of 73 years), with untreated CLL and coexisting conditions, obinutuzumab plus chlorambucil was compared with rituximab plus chlorambucil.

In this trial, obinutuzumab plus chlorambucil resulted in a complete response rate of 20.7% compared to 7.0% for rituximab plus chlorambucil.

Furthermore, the obinutuzumab combination resulted in a median progression-free survival (PFS) rate of 26.7 months, compared with just 16.3 months for the rituximab combination.

I like this approach because not only does it provide treatment options for patients that would not have been indicated for rituximab, but also it also significantly increases the PFS rate and the response rate, without increasing the risk of treatment induced infection.

Obinutuzumab Plus Chlorambucil In Patients With CLL And Coexisting Conditions

LEARN ABOUT THE NEW CLINICAL DATA ON THE BENEFITS OF GREEN TEA FOR CLL


Speak Your Mind

*